# The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line

> **NCT02962388** · PHASE2,PHASE3 · TERMINATED · sponsor: **French Innovative Leukemia Organisation** · enrollment: 13 (actual)

## Conditions studied

- Essential Thrombocythemia

## Interventions

- **DRUG:** Anagrelide
- **DRUG:** Ruxolitinib (JAKAVI®)
- **DRUG:** IFNα/ PegIFNα

## Key facts

- **NCT ID:** NCT02962388
- **Lead sponsor:** French Innovative Leukemia Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01-03
- **Primary completion:** 2021-06-28
- **Final completion:** 2021-06-28
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** not enough recruitment
- **Last updated:** 2021-06-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02962388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02962388, "The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02962388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*